Citation

Wiese WG, Cichocka A, Krysztowiak-Wiese JM, Rozenek EB, Waszkiewicz N. Psychiatria (2004) 2022; 19(4): 286-291.

Copyright

(Copyright © 2022, Via Medica)

DOI

10.5603/PSYCH.2022.0008

PMID

unavailable

Abstract

Depression is one of the leading causes of disability worldwide, and 15% of patients with depression commit suicide. One of the milestones in the diagnosis and treatment of depression is to determine its exact pathophysiology. Currently, there are many theories on this subject, the most popular of which considers dysregulation of the immune system as the most important cause of the development of depression. It is now known that depressed patients have abnormal levels of inflammatory markers in their blood serum and cerebrospinal fluid. Moreover, recent clinical studies indicate that inflammatory biomarkers may be helpful both in diagnosis and in monitoring the effectiveness of treatment for depression. Monotherapy with anti-inflammatory drugs has antidepressant effects, and as add-on treatment, anti-inflammatory drugs improve the effects of antidepressants. The purpose of the following review is to present recent findings on inflammatory markers in depression. © 2022 Via Medica. All rights reserved.

Language: pl

Keywords

human; Review; depression; inflammation; TNF-α; pathophysiology; SSRI; biological marker; IFN-α; IFN-β